Zambon Group

Zambon S.p.a.

Newron Pharmaceuticals S.p.a.

Serentrix, LLC

Isagro S.p.a.

Ario Pharma Limited

Isagro S.p.a. and Zambon Group S.p.a.

Mauro Napoletano

Gabriele Morazzoni

Franco Pellacini

Gabriele Pietro Norcini

Giancarlo Grancini

Ermanno Moriggi

Andrea Mereu

Fernando Ornaghi

Patricia Salvati

Dario Chiarino

Carla Caccia

Florian Thaler

Alessandra Restivo

Cibele Sabido-David

Laura Faravelli

Francesca Fruttarolo

Maria Giovanna Pavani

Cristina Fraire

Francesco Santangelo

Marco Villa

Aldo Belli

Alberto Sala

Daniela Botta

Gian Carlo Grancini

Marcello Trevisani

Giovanna Schioppacassi

Enrico Albini

Gian Marco Leali

Luciano Pacchetti

Carlo Riva

Roberto Longoni

Livius Cotarca

Angelo Carenzi

Massimo Verzini

Dario Braga

Davide Della Bella

Paolo Maragni

Stefania Montanari

Paolo Cavalleri

Julio Alvarez-Builla

Ivan Michieletto

Roberto Brescello

Angelo Restelli

Franco Massaccesi

Lorenzo Pradella

Carlo Veneziani

Elisa Melotto

Francesco Ponzini

Jos&eacute; Luis Garcia Navaio

Jorge G Siro Herrero

Biase Continanza

Fabio Rondina

Alessandro Di Maria

Raffaele Gatti

Serena Bencivenni

Dario Università Di Bologna Braga

The invention discloses compounds of formula I   The compounds of formula I are TRPV1 antagonists and are useful as active ingredients of pharmaceutical compositions for the treatment of pain and other conditions ameliorated by the inhibition of the vanilloid receptor TRPV1.

TRPV1 vanilloid receptor antagonists with a bicyclic portion

The invention discloses compounds of Formula (I). The compounds of formula (I) are TRPA1 antagonists and are useful as active ingredients of pharmaceutical compositions for the treatment of pain and other conditions ameliorated by the inhibition of TRPA1 receptors. 

Sulfonamide TRPA1 receptor antagonists

2-Phenylethylamino substituted carboxamide derivatives and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies are presented.

2-phenylethylamino derivatives as calcium and/or sodium channel modulators

The present invention relates to macrolide compounds endowed with antiinflammatory activity and more particularly relates to new stable crystalline forms of a macrolide derivative with antiinflammatory activity, processes for the preparation of such forms, pharmaceutical compositions containing them as active ingredient and the use of said crystalline forms for the treatment of inflammatory diseases.

Crystalline forms of macrolide compounds endowed with antiinflammatory activity

2-Phenylethylamino substituted carboxamide derivatives of formula (I); wherein J, W, R, R, R, R, and Rhave the meanings as defined in the specification and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them as active ingredient and their use as sodium and/or calcium channel modulators useful in preventing alleviating and curing a wide range of pathologies, including neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urology, and gastrointestinal diseases where the above mechanisms have been described as playing a pathological role, are described. 

The present invention relates to new pharmaceutical uses of an isoxazolic derivative or a pharmaceutically acceptable salt thereof in the preparation of a medicament useful for treating the neuropathic pain.

Isoxazolic derivative to relieve neuropathic pain

Macrolide compounds endowed with antiinflammatory activity are described, and more particularly macrolide derivatives lacking cladinose in position 3, with antiinflammatory activity, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing them as active ingredient.

Macrolide compounds endowed with antiinflammatory activity

Macrolide compounds of formula (I) wherein X, R, R, R, Rand R, have the meanings as defined in the specification, pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them as active ingredient and the use thereof in the treatment and prophylaxis of inflammatory diseases, are described. 

Macrolides with antiinflammatory activity

Macrolide compounds lacking cladinose in position 3 having antiinflammatory activity and substantially free of antibiotic properties, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing them as active ingredient.

Macrolides with anti-inflammatory activity are described. Particularly described are 9a-azalides and their anti-inflammatory activity without cladinose in position 3, the pharmaceutically acceptable salts thereof and the pharmaceutical composition that contain them as active principle.

9a-azalides with anti-inflammatory activity

A process for the preparation of phthalazines by preparing intermediate (pyridinylidene)-phthalides starting from 3-oxo-1,3-dihydro-isobenzofuran-1-carboxylic acids and pyridinecarbaldehydes, is described.

Process for the preparation of (pyridinylidene)-phthalides

A process for the preparation of (pyridinylidene)-phthalides starting from 3-oxo-1,3-dihydro-isobenzofuran-1-carboxylic acids and pyridinecarbaldehydes, is described.

Compounds of formula (I) wherein B is alkylene, amino, CONH or a bond; Cy is optionally substituted phenyl or heteroaryl; R is H, phenyl or (C )alkyl optionally substituted; R is (C )alkyl or polyfluoro(C )-alkyl; R is (C )cycloalkyl optionally containing an oxygen atom and optionally substituted; and the N&rarr;O derivatives and pharmaceutically acceptable salt thereof are PDE 4 and TNF&agr; inhibitors.

Phthalazine derivatives as phosphodiesterase 4 inhibitors

Growing community of inventors

Milan, Italy

Mauro Napoletano